Live Breaking News & Updates on Biocon Cancer Drug Europe

Biocon may bag approval for cancer drug in European market
Once approved, the product can be marketed in the 27 European Union (EU) member countries and European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein
Joe C Mathew | March 1, 2021 | Updated 12:03 IST
Biocon Biologics Ltd, a subsidiary of Biocon Ltd is one step closer to bagging a marketing approval for its biosimilar cancer drug Bevacizumab in the European Union member countries.  
The company said the product received a positive response from the European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP). With the committee recommending the marketing authorisation of Bevacizumab, the company now needs final approval from the European Commission (EC), expected by May 2021. ....

United States , United Kingdom , Kiran Mazumdar Shaw , Roche Avastin , Biocon Biologics , Biocon Biologics Ltd , European Union , European Commission , Biocon Ltd , Healthcare Products Regulatory Agency , European Medicines Agency , Medicinal Products , Human Use , Executive Chairperson , European Economic Area , Biocon Biologic , Biocon Cancer Drug , Biocon Europe , Biocon Cancer Drug Europe , Bevacizumab Cancer Drug , Bevacizumab Biocon , Bevacizumab Biocon Cancer Drug , Bevacizumab Europe , Bevacizumab Biocon Europe , Bevacizumab Cancer Drug Europe , ஒன்றுபட்டது மாநிலங்களில் ,